Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 415 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ARDS (Acute Respiratory Distress Syndrome) Clear all
Completed Phase 1 Interventional

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

NCT04468971
View directory record Official record
Conditions
COVID19, ARDS
Interventions
CK0802, Placebo
Biological · Drug
Lead sponsor
Cellenkos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

NCT04315298
View directory record Official record
Conditions
COVID-19
Interventions
Sarilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
62
States / cities
Los Angeles, California • Sacramento, California • Santa Monica, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 2, 2026, 5:18 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Breathing Patterns in Infants Before and After Extubation

NCT07542301
View directory record Official record
Conditions
Respiratory Distress Syndrome (RDS), PreTerm Neonate
Interventions
Observation
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
0 Days to 6 Months
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 2, 2026, 5:18 AM EDT
Completed No phase listed Observational

Blood Volume Assessment in COVID-19 and Bacterial Sepsis

NCT04517695
View directory record Official record
Conditions
Covid19, Acute Respiratory Distress Syndrome, Bacterial Sepsis, Bacterial Infections
Interventions
BVA-100, Transpulmonary Thermodilution (TPTD), Sublingual Microcirculation
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 95 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Bethesda, Maryland • New York, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

Iloprost Effects on Gas Exchange and Pulmonary Mechanics

NCT01274481
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Acute Lung Injury, Pulmonary Hypertension
Interventions
Iloprost
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 2, 2026, 5:18 AM EDT
Completed No phase listed Observational

Genetic Regulation of Surfactant Deficiency

NCT00828243
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Nutrient
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day to 6 Months
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 2, 2026, 5:18 AM EDT
Terminated Phase 3 Interventional

Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)

NCT00609180
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Minimal (Trophic) Feeding, Full Feeding, Omega-3 Fatty Acids and Antioxidant Supplements, Placebo
Behavioral · Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS

NCT04582201
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
agenT-797
Drug
Lead sponsor
MiNK Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Santa Monica, California • Louisville, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 2, 2026, 5:18 AM EDT
Enrolling by invitation Not applicable Interventional

Surfactant Using a Supraglottic Airway Device in Late Preterm to Early Term Infants

NCT07176117
View directory record Official record
Conditions
Respiratory Distress Syndrome (Neonatal), Surfactant
Interventions
Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA), Continuous Positive Airway Pressure (CPAP)
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
33 Weeks to 38 Weeks
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Chula Vista, California • La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 2, 2026, 5:18 AM EDT
Recruiting Phase 2 Interventional

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

NCT06701669
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort B: paridiprubart, Cohort B: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 2, 2026, 5:18 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

NCT04369469
View directory record Official record
Conditions
COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
Interventions
Ravulizumab, BSC
Biological · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 2, 2026, 5:18 AM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 2, 2026, 5:18 AM EDT
Terminated Not applicable Interventional

Open Lung Strategy, Gas Distribution and Right Heart Function in ARDS Patients

NCT03202641
View directory record Official record
Conditions
ARDS, Human, Lung Injury, Acute, Respiratory Distress Syndrome, Mechanical Ventilation Complication, Alveolar Edema, Right Heart Failure, Right Ventricular Dysfunction
Interventions
PEEP ARDSnet, PEEP LRM
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 2, 2026, 5:18 AM EDT
Not listed No phase listed Observational

Application of Lung Near-Infrared Spectroscopy (NIRS) in Preterm Infants

NCT05961670
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Neer Infrared Spectroscopy
Device
Lead sponsor
Keck School of Medicine of USC
Other
Eligibility
1 Hour to 24 Hours
Enrollment
50 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Not applicable Interventional

Late Permissive Hypercapnia for Intubated and Ventilated Preterm Infants

NCT02799875
View directory record Official record
Conditions
Premature Neonate
Interventions
Higher permissive hypercapnia, Lower Permissive Hypercapnia
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
7 Days to 14 Days
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 2, 2026, 5:18 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

NCT04565665
View directory record Official record
Conditions
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Mesenchymal Stem Cell
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 2, 2026, 5:18 AM EDT
Not listed No phase listed Observational

Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study

NCT01806532
View directory record Official record
Conditions
Respiratory Failure
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Not applicable Interventional

Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)

NCT00814099
View directory record Official record
Conditions
Respiratory Insufficiency, Respiratory Distress Syndrome, Newborn, Lung Diseases
Interventions
Team approach to sedation management, Usual approach to sedation management
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
2 Weeks to 18 Years
Enrollment
2,449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Oakland, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 2, 2026, 5:18 AM EDT
Terminated Phase 2 Interventional

Activated Protein C to Treat Acute Lung Injuries

NCT00112164
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Xigris
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
9
States / cities
Fresno, California • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 2, 2026, 5:18 AM EDT
Completed No phase listed Observational

Observational Crossover Study Comparing Oxygenation and Ventilation Using SiPAP Versus CPAP in LBW Infants

NCT01053455
View directory record Official record
Conditions
Ventilation, Respiratory Distress Syndrome
Interventions
SiPAP
Device
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Phase 4 Interventional

Sleep Intervention During Acute Lung Injury

NCT01050699
View directory record Official record
Conditions
Critical Illness, Sleep, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Dexmedetomidine, Midazolam and Fentanyl
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 2, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

NCT01335932
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions
IV Ganciclovir, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
14
States / cities
Denver, Colorado • Chicago, Illinois • Springfield, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 2, 2026, 5:18 AM EDT
Suspended Phase 1 Interventional

Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)

NCT05387278
View directory record Official record
Conditions
COVID-19 Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome
Interventions
EV-Pure™ and WJ-Pure™, Placebo
Drug
Lead sponsor
Vitti Labs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Liberty, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 5:18 AM EDT
Enrolling by invitation Not applicable Interventional

Personalized Ventilator Settings for Patients on ECMO

NCT07673250
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation, Respiratory Failure Patients Treated With ECMO, Respiratory Failure, ICU, Ventilator Induced Lung Injury
Interventions
Personalized Positive End-Expiratory Pressure (PEEP)
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 2, 2026, 5:18 AM EDT